Top 1

Cytokinetic’s Aficamten Push Bests SOC In Heart Muscle Disorder

Precigen Scores FDA Approval Of Immunotherapeutic PAPZIMEOS For Rare Respiratory Disease

Novartis’ Win Streak With Ianalumab Continues With Solid ITP Treatment Data Release

Eli Lilly’s Stock Price Drops As Oral GLP-1 Achieves Moderate Weight Loss In Late-Stage Testing

Vertex’s Phase 2 Failure Leaves Next-Gen VX-993 Pain Drug On The Chopping Block

Cardiff’s Onvansertib Shows To Be Helpful To RAS-Mutated Colorectal Cancer Patients

CHMP Negative Opinion On ELEVIDYS Brings Further Woes For Sarepta And Its Partner Roche

Abivax’s Successful Phase 3 Ulcerative Colitis Trial Shows Obefazimod Differentiation

FDA Rejects Approval Of Replimune’s RP1 For Advanced Melanoma Patients, Type A Meeting Could Possibly Be Next Move

Third Patient Death That Dealt With LGMD Gene Therapy Puts Sarepta’s Pipeline At Risk

Kairos Pharma Posts Positive Safety Data With Use Of ENV105 For Advanced Prostate Cancer

MiNK Achieves Complete Remission With Allogeneic Off-The-Shelf AgenT-797 In Testicular Cancer Patient

To Get Wet-AMD Gene Therapy To Finish Line 4DMT Reduces Workforce By 25%

Nektar’s Rezpeg Hopes Revived After Latest Atopic Dermatitis Treatment Data

Kymera Achieves Positive STAT6 Protein Degrader Results In Healthy Volunteer Study

Pfizer Wants To Throw Its Hat Into The Ring With Up To $6 Billion 3SBio Deal

Bristol-Myers Squibb Fails Phase 3 Study With Cobenfy

Scroll to Top